Article info
PDFCardiac risk factors and prevention
Original article
Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality
- Correspondence to Dr Simon G Anderson, Institute of Cardiovascular Sciences, University of Manchester, 3.24 Core Technology Facility, 46 Grafton Street, Manchester M13 9NT, UK; simon.anderson{at}manchester.ac.uk
Citation
Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality
Publication history
- Received December 22, 2015
- Revised April 20, 2016
- Accepted May 23, 2016
- First published July 26, 2016.
Online issue publication
February 03, 2017
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/